GSK3B and breast carcinoma: Overexpression of GSK-3β in TNBC cells can inhibit Nrf2 expression, increase ROS and MDA levels, enhance erastin-induced ferroptosis, and in an in vivo breast cancer xenograft model, GSK-3β overexpression enhances the tumor growth-inhibiting effect induced by erastin.